Transgene Biotek Schedules Q2 FY27 Results Review for Nov 13

Transgene Biotek Ltd will review unaudited Q2 and H1 FY27 financial results at its board meeting on November 13, 2026. The meeting is also scheduled to consider a limited review report, a proposed one-year reappointment of its Chairman and Managing Director, and matters connected with its 36th annual general meeting.

When will Transgene Biotek announce its Q2 FY27 results?

Transgene Biotek has scheduled its board meeting for Friday, November 13, 2026, to consider financial results for the quarter and half-year ended September 30, 2026. The company said the meeting is planned for 4:00 PM in Chennai, and the results will be unaudited and subject to the auditor's limited review.

The disclosure covers both the September quarter, known as Q2 FY27, and the first half of FY27. While the company has referred to standalone and consolidated results in its announcement, the detailed meeting notice specifically refers to approval of unaudited standalone results along with the limited review report. Further details are expected to be filed with the stock exchange after the board meeting, where applicable.

No Q2 FY27 revenue, profit, margin, or earnings-per-share figures had been disclosed in the material provided before the meeting. Investors will therefore need to rely on the formal results filing for the company's financial performance during the September quarter.

What will the board consider besides the quarterly results?

Transgene Biotek's board is scheduled to consider several governance and compliance matters alongside the September-quarter financial statements. These include the limited review report, the notice for the 36th annual general meeting, adoption of the annual report for FY26, and the record date and e-voting arrangements related to the meeting.

The board will also consider reappointing Dr K. Koteswara Rao as Chairman and Managing Director for one more year. The proposed reappointment remains subject to shareholder approval. The company has also indicated that it will consider appointing a scrutiniser for e-voting, a procedural requirement for shareholder resolutions.

These agenda items place the November 13 meeting beyond a routine earnings announcement. The board is addressing both the financial reporting cycle and corporate-governance actions that will require subsequent disclosures and, in the case of the managing director's reappointment, shareholder consideration.

Why is the limited review process relevant before the results?

The limited review is relevant because Transgene Biotek has disclosed recent changes in its statutory-auditor position. Harish Gummadi & Co resigned with effect from November 3, 2026, citing unforeseen circumstances arising from a family medical emergency. The firm had been appointed on November 2 and had not issued any report, according to the disclosure.

Separately, the company disclosed that Vasavi & Co had resigned on October 31, 2026, citing pre-occupation. The disclosure described this as the second auditor exit in a month and said no audit qualification had been flagged. Transgene Biotek said a new auditor would be appointed, while the Q2 limited review was due by November 14, 2026.

The auditor changes are important for the timing and completion of the September-quarter review process. The company has not disclosed a qualification in connection with either auditor departure in the information provided. Investors will be able to assess the final reporting position through the results announcement and any related exchange filing.

What is known about Transgene Biotek's recent financial position?

Transgene Biotek reported a standalone net loss of ₹0.389 crore in Q1 FY27, compared with a net loss of ₹0.4337 crore in Q1 FY26. The company described the narrower loss as reflecting cost control, and stated that consolidated results mirrored the standalone figures.

The Q1 FY27 results were approved by the board on August 7, 2026. The provided information also notes pending legal proceedings involving the Securities Appellate Tribunal, National Company Law Tribunal, and Enforcement Directorate. No further financial or case-specific updates were included in the material for the November board meeting.

At a cited market price of ₹2.55, Transgene Biotek is categorised as a micro-cap healthcare services company. For such companies, a quarterly result filing can be significant because limited publicly available operating data may leave investors dependent on exchange disclosures for current financial information.

How does the meeting affect investors and trading in Transgene Biotek shares?

Transgene Biotek has kept its trading window closed from October 1, 2026, for directors, key managerial personnel, designated employees, and connected persons covered by the SEBI insider-trading rules. The restriction will continue until 48 hours after the declaration of the limited-reviewed financial results for the quarter ended September 30, 2026.

The closure is a standard compliance measure during a period when unpublished price-sensitive information may be available internally. It does not indicate the direction of the financial result. However, it identifies the November 13 board meeting and subsequent filing as the immediate event through which investors may receive updated operating and financial data.

For shareholders, the key disclosures to monitor are the reported Q2 and H1 FY27 figures, the status of the limited review, any update on auditor appointment, and the board's decision on the proposed CMD reappointment. The company has not released Q2 FY27 financial figures in advance, so the market impact cannot be quantified from the pre-meeting announcement alone.

Conclusion

Transgene Biotek's November 13 board meeting combines the approval of Q2 and H1 FY27 financial results with governance decisions including the proposed one-year reappointment of Dr K. Koteswara Rao. The meeting also follows two disclosed statutory-auditor exits within a month, making the limited review and related reporting disclosures particularly relevant.

Investors should watch for the formal exchange filing after the meeting, including the September-quarter financial statements, limited review outcome, auditor-related update, and AGM resolutions. The trading window is scheduled to remain closed until 48 hours after the limited-reviewed results are declared.